We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RPS20
SECTIONS
  • TISSUE
  • BRAIN
  • SINGLE CELL TYPE
  • TISSUE CELL TYPE
  • PATHOLOGY
  • DISEASE
  • IMMUNE CELL
  • BLOOD PROTEIN
  • SUBCELLULAR
  • CELL LINE
  • STRUCTURE
  • INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
  • SARS-COV-2
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Patient ID
Tissue
Category
Cluster
Reliability
Brain region
Category
Brain region
Category
Brain region
Category
Cluster
Reliability
Cell type
Category
Cluster
Tissue
Cell type
Enrichment
Cancer
Prognosis
Cancer
Category
Cell type
Category
Cell lineage
Category
Cluster
Annotation
Disease
Location
Searches
Location
Cell line
Type
Phase
Reliability
Cancer type
Category
Cluster
Interacting gene
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Protein structure
In atlas
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • TISSUE CELL

  • PATHOLOGY

  • DISEASE

  • IMMUNE

  • BLOOD

  • SUBCELL

  • CELL LINE

  • STRUCTURE

  • INTERACTION

  • RPS20
PATHOLOGY TESTIS CANCER Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
ANTIBODIES
AND
VALIDATION
Dictionary
Testis cancer
Human pathology
Testis cancer
TESTIS CANCER - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

RPS20 is not prognostic in testis cancer


Stage:


Survival analysis
Current cut offi

Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.

:
Best expression cut offi

Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .

When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.

: 484.45
Median expressioni

Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.

: N/A
Median follow up timei

Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.

: N/A
P scorei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

N/A
5-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
5-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
TCGA RNA samplesi

RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average FPKM 573.5
Number of samples 134
Samples
Sample Description FPKM
TCGA-2G-AAH0-01A 30 years, male, white, stage:is, alive, 5477 days 1768.7
TCGA-2G-AAHL-01A 26 years, male, white, stage:i, alive, 7081 days 1213.2
TCGA-SN-A84X-01A 21 years, male, white, stage:is, alive, 312 days 1175.4
TCGA-ZM-AA06-01A 45 years, male, white, stage:ib, alive, 1498 days 1165.6
TCGA-ZM-AA0B-01A 32 years, male, white, stage:ia, alive, 838 days 1085.0
TCGA-ZM-AA0E-01A 39 years, male, white, stage:ia, alive, 811 days 1056.2
TCGA-2G-AAFM-01A 31 years, male, white, stage:iia, alive, 503 days 1027.0
TCGA-ZM-AA0N-01A 44 years, male, white, stage:ib, alive, 634 days 1012.7
TCGA-2G-AAG9-01A 25 years, male, white, stage:iiib, alive, 2234 days 994.2
TCGA-4K-AAAL-01A 31 years, male, white, stage:is, alive, 483 days 972.8
TCGA-VF-A8AE-01A 39 years, male, white, stage:ia, alive, 727 days 939.5
TCGA-ZM-AA0D-01A 34 years, male, white, stage:ia, alive, 848 days 936.0
TCGA-2G-AAFN-01A 26 years, male, white, stage:iiib, alive, 773 days 908.8
TCGA-2G-AAEX-01A 38 years, male, white, stage:is, alive, 1259 days 908.6
TCGA-2G-AAGE-01A 21 years, male, white, stage:is, alive, 2478 days 878.7
TCGA-2G-AAHG-01A 25 years, male, white, stage:i, alive, 1819 days 846.8
TCGA-2G-AAHP-01A 31 years, male, white, stage:is, alive, 5667 days 846.8
TCGA-2G-AAH8-01A 45 years, male, white, stage:iiic, alive, 2248 days 833.4
TCGA-XE-AANR-01A 24 years, male, white, stage:i, alive, 14 days 828.4
TCGA-VF-A8A9-01A 31 years, male, white, stage:ia, alive, 1119 days 821.3
TCGA-2G-AAKD-01A 18 years, male, white, stage:iii, alive, 6340 days 807.6
TCGA-2G-AAGF-01A 28 years, male, white, stage:is, alive, 2734 days 803.7
TCGA-YU-A90W-01A 45 years, male, white, stage:ia, alive, 1113 days 794.4
TCGA-2G-AAF8-01A 33 years, male, white, stage:ia, alive, 3911 days 790.5
TCGA-XE-AAO3-01A 33 years, male, asian, stage:i, alive, 2857 days 788.9
TCGA-ZM-AA0F-01A 35 years, male, white, stage:ia, alive, 681 days 767.5
TCGA-2G-AAGZ-01A 27 years, male, white, stage:iiia, alive, 5233 days 761.4
TCGA-XE-AAO6-01A 47 years, male, white, stage:ia, alive, 240 days 761.1
TCGA-VF-A8A8-01A 18 years, male, white, stage:ia, alive, 1131 days 753.4
TCGA-2G-AAL7-01A 32 years, male, white, stage:is, alive, 3991 days 717.9
TCGA-VF-A8AC-01A 29 years, male, white, stage:ia, alive, 1083 days 713.8
TCGA-SO-A8JP-01A 29 years, male, white, stage:i, alive, 540 days 702.4
TCGA-WZ-A7V5-01A 27 years, male, white, stage:i, alive, 1061 days 699.0
TCGA-XE-AAO4-01A 40 years, male, white, stage:ia, alive, 367 days 695.1
TCGA-2G-AAFO-01A 33 years, male, white, stage:iia, alive, 685 days 694.5
TCGA-WZ-A8D5-01A 38 years, male, white, alive, 774 days 690.7
TCGA-S6-A8JX-01A 27 years, male, white, stage:ib, alive, 552 days 690.0
TCGA-XE-A8H5-01A 29 years, male, stage:is, alive, 1217 days 688.7
TCGA-VF-A8AA-01A 51 years, male, white, stage:i, alive, 1146 days 669.8
TCGA-SB-A6J6-01A 22 years, male, white, stage:ia, alive, 413 days 666.2
TCGA-2G-AAKG-01A 22 years, male, white, stage:i, alive, 6598 days 664.8
TCGA-2G-AAKL-01A 26 years, male, white, stage:ii, alive, 7023 days 658.3
TCGA-XE-AAOL-01A 38 years, male, black or african american, stage:i, alive, 13 days 651.5
TCGA-XE-AAOF-01A 50 years, male, asian, stage:ia, alive, 1268 days 649.9
TCGA-2G-AAGW-01A 38 years, male, white, stage:is, alive, 4899 days 647.2
TCGA-2G-AAF4-01A 30 years, male, white, stage:i, alive, 2315 days 647.0
TCGA-2G-AAF6-01A 28 years, male, white, stage:is, alive, 3491 days 637.5
TCGA-2G-AAG3-01A 53 years, male, white, stage:is, alive, 1593 days 632.6
TCGA-4K-AA1G-01A 34 years, male, white, stage:is, alive, 436 days 618.4
TCGA-XY-A9T9-01A 37 years, male, white, stage:is, alive, 281 days 615.8
TCGA-W4-A7U2-01A 26 years, male, white, alive, 1263 days 612.9
TCGA-XE-A9SE-01A 35 years, male, white, stage:ia, alive, 708 days 606.4
TCGA-2G-AAFL-01A 35 years, male, white, stage:ib, alive, 750 days 601.4
TCGA-4K-AA1I-01A 26 years, male, white, stage:ia, alive, 3 days 595.5
TCGA-SB-A76C-01A 38 years, male, white, alive, 42 days 587.4
TCGA-XE-AAOJ-01A 24 years, male, white, stage:is, alive, 1550 days 579.9
TCGA-ZM-AA0H-01A 50 years, male, white, stage:is, alive, 1736 days 578.8
TCGA-VF-A8AB-01A 31 years, male, black or african american, stage:ia, alive, 760 days 572.8
TCGA-2G-AAGA-01A 38 years, male, white, stage:iia, alive, 2439 days 569.9
TCGA-XE-AANV-01A 52 years, male, stage:ib, alive, 1701 days 569.6
TCGA-S6-A8JY-01A 27 years, male, white, stage:is, alive, 278 days 561.6
TCGA-XE-AANI-01A 37 years, male, white, stage:is, alive, 1041 days 556.2
TCGA-2G-AAHT-01A 32 years, male, white, stage:is, alive, 542 days 550.8
TCGA-2G-AAGO-01A 41 years, male, white, stage:is, alive, 4026 days 542.1
TCGA-2G-AAFH-01A 38 years, male, white, stage:iib, alive, 1375 days 535.2
TCGA-2G-AAH3-01A 20 years, male, white, stage:i, alive, 1822 days 526.0
TCGA-W4-A7U4-01A 23 years, male, white, alive, 738 days 523.6
TCGA-XE-AANJ-01A 39 years, male, white, stage:is, alive, 2007 days 518.0
TCGA-2X-A9D5-01A 49 years, male, white, stage:i, alive, 435 days 507.8
TCGA-2G-AAG8-01A 21 years, male, white, stage:ib, alive, 2289 days 504.0
TCGA-WZ-A7V3-01A 20 years, male, white, stage:i, alive, 753 days 497.5
TCGA-2G-AAFI-01A 41 years, male, white, stage:ib, alive, 675 days 496.5
TCGA-SN-A84Y-01A 18 years, male, white, stage:is, alive, 524 days 493.3
TCGA-2G-AAHN-01A 32 years, male, white, stage:i, alive, 6445 days 492.5
TCGA-XE-A8H4-01A 23 years, male, white, stage:ia, alive, 559 days 492.3
TCGA-4K-AA1H-01A 26 years, male, white, stage:ia, alive, 518 days 492.1
TCGA-YU-A912-01A 34 years, male, black or african american, stage:iiic, alive, 866 days 491.3
TCGA-YU-A94D-01A 28 years, male, stage:iiib, alive, 2167 days 491.2
TCGA-SN-A6IS-01A 26 years, male, white, stage:is, alive, 496 days 487.5
TCGA-2G-AAGN-01A 41 years, male, white, stage:iiib, alive, 3656 days 486.8
TCGA-2G-AAL5-01A 31 years, male, white, stage:i, alive, 7437 days 485.1
TCGA-2G-AAEW-01A 31 years, male, white, stage:is, dead, 618 days 483.9
TCGA-XE-AAOD-01A 39 years, male, white, stage:ib, alive, 2058 days 482.4
TCGA-2G-AAFG-01A 30 years, male, white, stage:is, alive, 6183 days 479.7
TCGA-2G-AAGS-01A 39 years, male, white, stage:iiib, alive, 4816 days 471.9
TCGA-YU-A90Q-01A 21 years, male, stage:ib, alive, 1964 days 471.2
TCGA-2G-AALP-01A 43 years, male, white, stage:iiib, alive, 2645 days 470.1
TCGA-YU-A90Y-01A 23 years, male, black or african american, stage:iiic, dead, 17 days 458.2
TCGA-XE-A8H1-01A 24 years, male, white, stage:is, alive, 209 days 441.2
TCGA-2G-AAGC-01A 28 years, male, white, stage:is, alive, 2585 days 435.8
TCGA-2G-AAFJ-01A 23 years, male, asian, alive, 792 days 435.6
TCGA-2G-AAFY-01A 24 years, male, white, stage:iia, alive, 1099 days 426.8
TCGA-2G-AAH4-01A 34 years, male, white, stage:ii, alive, 6210 days 423.9
TCGA-2G-AAGJ-01A 28 years, male, black or african american, stage:ia, alive, 2938 days 423.0
TCGA-2G-AAH2-01A 20 years, male, white, stage:is, alive, 6060 days 414.1
TCGA-2G-AAKM-01A 14 years, male, white, stage:ii, dead, 6972 days 413.9
TCGA-2G-AAHC-01A 33 years, male, white, stage:is, alive, 5539 days 412.1
TCGA-S6-A8JW-01A 37 years, male, white, stage:is, alive, 698 days 404.8
TCGA-VF-A8AD-01A 36 years, male, white, stage:ib, alive, 1006 days 404.0
TCGA-XY-A89B-01A 35 years, male, white, stage:ia, alive, 471 days 401.9
TCGA-YU-A90S-01A 26 years, male, white, stage:ia, alive, 971 days 401.8
TCGA-2G-AAF1-01A 28 years, male, asian, stage:is, alive, 1403 days 400.0
TCGA-ZM-AA05-01A 36 years, male, white, stage:iic, alive, 1126 days 394.2
TCGA-2G-AAHA-01A 48 years, male, white, stage:ib, alive, 3349 days 392.8
TCGA-2G-AAGV-01A 23 years, male, white, alive, 4527 days 392.5
TCGA-XE-AAOB-01A 27 years, male, white, stage:is, dead, 513 days 383.7
TCGA-2G-AAGX-01A 22 years, male, white, stage:ia, alive, 5514 days 371.9
TCGA-2G-AAKH-01A 19 years, male, white, stage:ii, alive, 6862 days 370.6
TCGA-2G-AAFZ-01A 32 years, male, white, stage:iii, alive, 1353 days 369.0
TCGA-WZ-A7V4-01A 28 years, male, white, stage:i, alive, 894 days 367.5
TCGA-XY-A8S2-01A 67 years, male, white, stage:i, alive, 672 days 366.8
TCGA-2G-AAFE-01A 37 years, male, white, stage:iia, alive, 4702 days 361.9
TCGA-X3-A8G4-01A 33 years, male, white, stage:is, alive, 856 days 356.8
TCGA-YU-A90P-01A 25 years, male, white, stage:ia, alive, 2069 days 346.2
TCGA-2G-AAG5-01A 36 years, male, white, stage:is, alive, 2299 days 338.7
TCGA-2G-AAGG-01A 20 years, male, white, stage:iiic, alive, 2611 days 331.5
TCGA-YU-AA61-01A 29 years, male, white, stage:is, alive, 864 days 325.5
TCGA-2G-AAGM-01A 51 years, male, white, stage:is, alive, 3891 days 316.7
TCGA-2G-AAG6-01A 24 years, male, white, stage:is, alive, 2231 days 305.7
TCGA-XY-A8S3-01B 24 years, male, white, stage:is, alive, 843 days 304.3
TCGA-2X-A9D6-01A 42 years, male, white, stage:i, alive, 607 days 304.0
TCGA-2G-AAGY-01A 28 years, male, white, stage:is, alive, 5329 days 301.6
TCGA-2G-AAG0-01A 23 years, male, white, stage:is, alive, 1529 days 300.7
TCGA-SN-A84W-01A 30 years, male, white, stage:is, alive, 293 days 295.9
TCGA-2G-AAGI-01A 33 years, male, white, stage:is, alive, 3137 days 290.7
TCGA-2G-AAGP-01A 33 years, male, white, stage:iia, alive, 4018 days 284.7
TCGA-2G-AAGK-01A 20 years, male, white, stage:is, alive, 3621 days 281.4
TCGA-YU-AA4L-01A 27 years, male, black or african american, stage:iiic, alive, 1573 days 260.2
TCGA-XE-AAOC-01A 31 years, male, white, stage:ia, alive, 270 days 232.3
TCGA-2G-AAG7-01A 33 years, male, white, stage:is, alive, 2475 days 218.9
TCGA-W4-A7U3-01A 26 years, male, white, alive, 149 days 201.4
TCGA-2G-AAFV-01A 31 years, male, white, stage:is, alive, 1389 days 182.7
TCGA-2G-AAGT-01A 30 years, male, white, stage:is, alive, 4406 days 128.2
TCGA-YU-A94I-01A 66 years, male, stage:ia, alive, 536 days 119.3
Show allShow less
TESTIS CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA003570
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Click images for details

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org